[
  {
    "ts": "2025-11-05T02:11:19+00:00",
    "headline": "Vertex Pharmaceuticals (VRTX) Returns to Profitability, Challenging Bearish Narratives on Earnings Quality",
    "summary": "Vertex Pharmaceuticals (VRTX) swung to profitability as the company left behind five years of annual earnings declines averaging 10.4%. Looking ahead, management projects earnings growth of 13.3% per year and revenue growth of 8.8%, both trailing the broader US market’s respective forecasts of 16% and 10.5%. With margins turning positive and a high quality of earnings now established, investors will be watching continued profit momentum. The share price of $421.67 remains well below an...",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-returns-profitability-021119103.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "954a3b4e-9074-3943-bb6a-c11c5e0ca9e0",
      "content": {
        "id": "954a3b4e-9074-3943-bb6a-c11c5e0ca9e0",
        "contentType": "STORY",
        "title": "Vertex Pharmaceuticals (VRTX) Returns to Profitability, Challenging Bearish Narratives on Earnings Quality",
        "description": "",
        "summary": "Vertex Pharmaceuticals (VRTX) swung to profitability as the company left behind five years of annual earnings declines averaging 10.4%. Looking ahead, management projects earnings growth of 13.3% per year and revenue growth of 8.8%, both trailing the broader US market’s respective forecasts of 16% and 10.5%. With margins turning positive and a high quality of earnings now established, investors will be watching continued profit momentum. The share price of $421.67 remains well below an...",
        "pubDate": "2025-11-05T02:11:19Z",
        "displayTime": "2025-11-05T02:11:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihFoSuY9PLXURl2kI_sV.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bIz6sh0rX4c7ACsVP8z51w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-returns-profitability-021119103.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-returns-profitability-021119103.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-05T16:35:00+00:00",
    "headline": "VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?",
    "summary": "VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.",
    "url": "https://finance.yahoo.com/news/vrtxs-drugs-performance-mixed-q3-163500527.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "646ecce3-3fe5-361f-b4ae-8996f3f0efa7",
      "content": {
        "id": "646ecce3-3fe5-361f-b4ae-8996f3f0efa7",
        "contentType": "STORY",
        "title": "VRTX's New Drugs Performance Mixed in Q3: Can Their Sales Improve?",
        "description": "",
        "summary": "VRTX's new drugs deliver a mixed Q3 performance. Alyftrek sales surge. Journavx and Casgevy lag expectations but show promise.",
        "pubDate": "2025-11-05T16:35:00Z",
        "displayTime": "2025-11-05T16:35:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kOx_hEoutoKbvEBeeXdzsA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F9I2cfbMe3krq0DVrblX.g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/96776645e0ac7ab203b7d5e3b37251a6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vrtxs-drugs-performance-mixed-q3-163500527.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vrtxs-drugs-performance-mixed-q3-163500527.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]